Publication: Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017.
Loading...
Identifiers
Publication date
Authors
García Castillo, Elena
Alonso Pérez, Tamara
Peláez, Adrián
Pérez González, Patricia
Miravitlles, Marc
Alfageme, Inmaculada
Casanova, Ciro
Cosío, Borja G
de Lucas, Pilar
García-Río, Francisco
Advisors
Journal Title
Journal ISSN
Volume Title
Publishers
Elsevier
Abstract
Introduction: We aim to describe the changes in prevalence and risk factors associated to chronic obstructive pulmonary disease (COPD) in Spain, comparing three population-based studies conducted in three timepoints.
Methods: We compared participants from IBERPOC conducted in 1997, EPISCAN conducted in 2007 and EPISCAN II in 2017. COPD was defined as a postbronchodilator FEV1/FVC (forced expiratory volume in 1s/forced vital capacity) ratio <0.70, according to GOLD criteria; subsequently, also as the FEV1/FVC below the lower limit of normal (LLN).
Results: COPD prevalence in the population between 40 and 69 years decreased from 21.6% (95% CI 20.7%-23.2%) in 1997 to 8.8% (95% CI 8.2%-9.5%) in 2017, a 59.2% decline (p<0.001). In 2007, the prevalence was 7.7% (95% CI 6.8%-8.7%) with an upward trend of 1.1 percentage points in 2017 (p=0.073). Overall COPD prevalence decreased in men and women, although a significant increase was observed in the last decade in females (p<0.05). Current smokers significantly increased in the last decades (25.4% in 1997, 29.1% in 2007 and 23.4% in 2017; p<0.001). Regrettably, COPD underdiagnosis was constantly high, 77.6% in 1997, 78.4% in 2007, and to 78.2% in 2017 (p=0.95), higher in younger ages (40-49 yrs and 50-59 yrs) and also higher in women than in men in all three studies (p<0.05).
Conclusions: We report a significant reduction of 59.2% in the prevalence of COPD in Spain from 1997 to 2017 in subjects aged 40-69 years. Our study highlights the significant underdiagnosis of COPD, particularly sustained in women and younger populations.
Description
IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, S.A. EPISCAN study was a GSKsponsored GlaxoSmithKline Spain. EPISCAN II study was a GSK sponsored study, registered in ClinicalTrials.gov Identifier: NCT01122758.
Keywords
MeSH Terms
DeCS Terms
Bibliographic citation
Arch Bronconeumol. 2023 Mar;59(3):142-151.





